Alpha Tau Medical Ltd.
NASDAQ:DRTSBiotechnology
+$0.04 today
- Market cap
- $1.12B
- Beta
- 1.20
- P/E (TTM)
- -15.2
- EPS (TTM)
- -$0.63
Volume 1.08M
Average 0.69M
Returns on capital
Alpha Tau Medical Ltd. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.3%
avg 628.1%
ROIC
-43.5%
avg -23.2%
ROA
-40.0%
avg -34.3%
Analysis
ROA is currently the strongest return metric at -40.0% versus its period average of -34.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Uzi Sofer | Chief Executive Officer & Chairman | USD 1.26M | 56 | 4.68K | <0.01% |
Raphi Levy | Chief Financial Officer | USD 763K | 41 | 90.18K | 0.10% |
Robert Den | Chief Medical Officer & Member of Scientific Advisory Board | USD 756K | 47 | — | — |
Ronen Segal | Chief Technology Officer | USD 435K | 53 | — | — |
Amnon Gat | Chief Operations Officer | USD 251K | 51 | — | — |
Yael Zeiger | Corporate Controller | — | 43 | — | — |
Rebecca Becker | Vice President of legal | — | — | — | — |
Yona Keisari | Chief Scientific Officer | — | 79 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 21, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$1.56M
Net Transaction Value
−$1.56M
Net selling
Most Active
Levy Raphi
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 21, 26Aug 21, 2026 | Levy Raphi Direct | Sell | $43.1K$43,073.04 |
| Aug 11, 26Aug 11, 2026 | Levy Raphi Direct | Sell | $248.3K$248,276.74 |
| Jul 6, 26Jul 6, 2026 | Levy Raphi Direct | Sell | $31.8K$31,782.50 |
| Jul 2, 26Jul 2, 2026 | Levy Raphi Direct | Sell | $232.4K$232,397.26 |
| Jul 1, 26Jul 1, 2026 | Levy Raphi Direct | Sell | $27.7K$27,691.20 |
| Jun 30, 26Jun 30, 2026 | Levy Raphi Direct | Sell | $240K$240,044.00 |
| Jun 25, 26Jun 25, 2026 | Levy Raphi Direct | Sell | $46.4K$46,442.84 |
| Jun 25, 26Jun 25, 2026 | Levy Raphi Direct | Sell | $173.6K$173,561.16 |
| Jun 23, 26Jun 23, 2026 | Levy Raphi Direct | Sell | $25K$25,001.00 |
| Jun 23, 26Jun 23, 2026 | Levy Raphi Direct | Sell | $142.1K$142,050.00 |
1–10 of 12
Summary
Insiders reported 0 buys worth $0.00 and 12 sells worth $1.56M over the last 12 months. That adds up to net selling of $1.56M. Levy Raphi was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Alpha Tau Medical Ltd. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DRTS's management, answered from reported figures.
Who manages DRTS?
Alpha Tau Medical Ltd. (DRTS) lists 8 active executives. The top listed executive is Yael Zeiger, Corporate Controller.
Are DRTS insiders buying or selling?
Recent insider activity shows net selling of $1.43M.
Continue the stock analysis
Jump to another research area for this company.